Article Content

Watch these interviews on the iPad edition of this issue, conducted by Sarah Maxwell

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.
 
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome

 

Giuseppe Curigliano MD, PhD, Director of the Early Drug Development for Innovative Therapies Division of the European Institute of Oncology in Milan, says that because harnessing the immune system is now proven as a way to manage breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes. He elaborates on his presentation at the meeting updating their role in mediating immune pathways in cancer, offering insights into how the "immunome" could be used as a target.

 

Targeting Emerging Druggable Pathways in Breast Cancer

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, describes the clinical significance of three key targetable pathways for breast cancer treatment-the CDK 4-6, PIK3CA, and FGFR pathways.

 

Breast Cancer Prognostic Implications of Obesity and Insulin Resistance

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Pamela J. Goodwin, MD, MSc, FRCPC, Professor of Medicine and Director of the Marvelle Koffler Breast Centre at the University of Toronto/Mount Sinai Hospital, discusses her long-terms research into obesity and insulin resistance, increasingly recognized as important targets for primary prevention of breast cancer.

 

Targeting Bone Microenvironment in Breast Cancer

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Michael Gnant MD, Professor and Director of Medical University of Vienna, reviews new data on the clinical potential of bone-directed therapies for breast cancer.

 

BCL-2 Therapeutic Target in ER-Positive Breast Cancer

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Geoffrey J. Lindeman, BSc(Med), PhD, Joint Head of the Stem Cells and Cancer Division of Walter and Eliza Hall Institute of Medical Research, Clinical Director of the ACRF Centre for Therapeutic Target Discovery, and Head of the Familial Cancer Centre at Royal Melbourne Hospital, discusses the clinical potential of modulation of BCL-2, a newly named therapeutic target for hormone-receptor positive breast cancer.

 

If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.